Endovascular treatment of acute ischemic stroke in the Netherlands for late arrivals
| ISRCTN | ISRCTN19922220 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN19922220 |
| Protocol serial number | NL58246.078.17 |
| Sponsor | Maastricht University Medical Center |
| Funder | Hartstichting |
- Submission date
- 21/09/2017
- Registration date
- 11/12/2017
- Last edited
- 07/05/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Ischaemic strokes occur when a blood clot blocks the flow of blood and oxygen to the brain. They occur about 20,000 times a year in the Netherlands. Since the mid-nineties, ischemic stroke has been treated with clot-dissolving medication (thrombolytics) within 4.5 hours after symptoms start. This treatment has a moderate effect on clinical improvement. A new, promising treatment option and important subject of research in the past 10 years is endovascular treatment (EVT). This involves removing the clot using a small tube (catheter). This method has been proved to be safe and effective if performed within 6 hours after the start of symptoms. However, many patients with ischemic stroke (up to 25%) arrive in the hospital after this 6 hour time-window. The aim of this study is to determine the safety and effectiveness of EVT between 6 and 24 hours after the start of symptoms.
Who can participate?
Patients aged 18 or older with acute ischemic stroke
What does the study involve?
Participants are randomly allocated to be treated with EVT or the best medical treatment. Every participant undergoes a scan of the brain blood vessels to assess the restoration of blood flow 24 hours later, and a brain scan to assess final infarct (dead tissue) volume 5-7 days later. Three months later all participants are interviewed by telephone to assess their functional outcome.
What are the possible benefits and risks of participating?
EVT may improve functional outcome when applied 6 to 24 hours after the start of symptoms. Based on previous studies, few complications are expected.
Where is the study run from?
1. Maastricht University Medical Center (Netherlands)
2. Academic Medical Center (Netherlands)
3. Erasmus Medical Center (Netherlands)
4. University Medical Center Utrecht (Netherlands)
When is the study starting and how long is it expected to run for?
May 2017 to November 2022
Who is funding the study?
Dutch Heart Foundation (Netherlands)
Who is the main contact?
Robert-Jan Goldhoorn
Contact information
Scientific
P. Debyelaan 25
Maastricht
6229 HX
Netherlands
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Multicenter phase III clinical trial with randomized treatment allocation, open label treatment and blinded endpoint evaluation (PROBE design) |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Multicenter randomised clinical trial of endovascular treatment of acute ischemic stroke in the Netherlands for late arrivals |
| Study acronym | MR CLEAN-LATE |
| Study objectives | Endovascular treatment for acute ischemic stroke due to an intracranial large vessel occlusion of the anterior circulation is effective for patients treated between 6 and 24 hours after symptom onset or last seen well less than 24 hours, after selection based on collateral flow. |
| Ethics approval(s) | Medisch Ethische Toetsings Commissie Erasmus MC (Medical Ethical Committee Erasmus MC), 11/09/2017, ref: MEC-2017-367 |
| Health condition(s) or problem(s) studied | Acute ischemic stroke due to an intracranial large vessel occlusion of the anterior circulation |
| Intervention | Randomisation: web-based; permuted blocks. Backup by telephone. The control group will receive best medical management. The intervention group will receive endovascular treatment (EVT). All patients in the intervention group will be transferred to the angiosuite. The procedure involves arterial catheterization, after which intracranial thrombectomy will be performed with a stent-retriever or other device approved by the steering committee. Every participant will undergo a CTA of the cerebral vessels to assess rate of recanalization 24 hours after randomization, and a brain scan to assess final infarct volume 5-7 days after randomization. Three months after inclusion all participants will be interviewed by telephone to determine functional outcome. |
| Intervention type | Procedure/Surgery |
| Primary outcome measure(s) |
Functional outcome, measured by the modified Rankin Scale (mRS) at 90 days |
| Key secondary outcome measure(s) |
1. Mortality at 90 days |
| Completion date | 01/11/2022 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 500 |
| Total final enrolment | 535 |
| Key inclusion criteria | 1. Clinical diagnosis of acute ischemic stroke 2. Caused by proximal intracranial anterior circulation occlusion (distal intracranial carotid artery or middle (M1/M2) cerebral artery confirmed by neuro-imaging (CTA or MRA) 3. Presence of poor*, moderate or good collateral flow as shown by neuroimaging (CTA) 4. CT or MRI ruling out intracranial hemorrhage 5. Start of IA treatment (groin puncture) possible between 6 and 24 hours after symptom onset or last seen well < 24 hours including wake-up strokes 6. A score of at least 2 on the NIH Stroke Scale 7. Age of 18 years or older *Inclusion and randomization will be restricted to patients with moderate or good collaterals when 100 patients with poor collaterals have been included in the study |
| Key exclusion criteria | 1. Pre-stroke disability which interferes with the assessment of functional outcome at 90 days, i.e. mRS >2 2. Cerebral infarction in the previous 6 weeks with residual neurological deficit or signs of large recent infarction on neuroimaging in the territory of the middle cerebral antery 3. Clinical evidence of hemorrhagic diathesis, confirmed by an INR > 3 and/or a platelet count < 40 x 109/L and/or an APTT > 50 sec 4. Clearly demarcated hypodensity in >1/3 of the middle cerebral artery territory, consistent with current symptoms 5. Participation in trials other than current and MR ASAP |
| Date of first enrolment | 01/11/2017 |
| Date of final enrolment | 01/11/2021 |
Locations
Countries of recruitment
- Netherlands
Study participating centres
6202 AZ
Netherlands
1005 AZ
Netherlands
3000 CA
Netherlands
3508 GA
Netherlands
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| IPD sharing plan | The data sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 29/03/2023 | 03/04/2023 | Yes | No | |
| Results article | 2-year follow-up | 25/06/2024 | 25/06/2024 | Yes | No |
| Protocol article | protocol | 07/01/2020 | 16/02/2021 | Yes | No |
| Protocol article | protocol | 24/02/2021 | 26/02/2021 | Yes | No |
| Other publications | post hoc secondary analysis of CTP parameters association of EVT with functional outcomes among patients in the late window after ischemic stroke selected based on collateral flow | 05/05/2025 | 07/05/2025 | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
07/05/2025: Publication reference added.
25/06/2024: Publication reference added.
03/04/2023: The following changes were made to the trial record:
1. Publication reference added.
2. The total final enrolment was added.
26/02/2021: Publication reference added.
16/02/2021: Publication reference added.
